{"url_path":"/sec/mgrx/8-k/2026-07-02/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1938046/0001493152-26-031917-index.html","accession_number":"0001493152-26-031917","cik":"0001938046","ticker":"MGRX","issuer_name":"MANGOCEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1938046/0001493152-26-031917-index.html","primary_entity_key":"0001938046","primary_entity_name":"MANGOCEUTICALS, INC."},"word_count":139,"has_tables":true,"body_markdown":"**Item\n1.01 Entry into a Material Definitive Agreement.**\n\n \n\n*Private\nPlacement Subscriptions*\n\n \n\nOn\nJune 29, 2026, Mangoceuticals, Inc. (the “Company”, “we” and “us”) entered into\na Subscription Agreement with an accredited investor (the “Investor”), pursuant to which the Investor purchased 850,000\nshares of restricted common stock from the Company, for $0.32 per share, or a total of $272,000. The Subscription Agreement included\ncustomary representations and warranties of the Investor and the Company and includes piggyback registration rights for a period of one\nyear following the dates of the subscription.\n\n \n\nThe\ndescription of the Subscription Agreement above is not complete and is qualified in its entirety by the full text of the form of Subscription\nAgreement, a copy of which is attached hereto as Exhibit 10.1, and which is incorporated by reference into this Item 1.01\nin its entirety by reference."}